User menu

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Bibliographic reference Papp, K A ; Griffiths, C E M ; Gordon, K ; Lebwohl, M ; Szapary, P O ; et. al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.. In: British Journal of Dermatology, Vol. 168, no. 4, p. 844-854 (2013)
Permanent URL
  1. Bissonnette R., Ho V., Langley R. G., Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis, 10.2310/7750.2009.00023
  2. Archier E., Devaux S., Castela E., Gallini A., Aubin F., Le Maître M., Aractingi S., Bachelez H., Cribier B., Joly P., Jullien D., Misery L., Paul C., Ortonne J.-P., Richard M.-A., Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review : Carcinogenic risks of PUV-A therapy and NB-UVB, 10.1111/j.1468-3083.2012.04520.x
  3. Naldi L., Griffiths C.E.M., Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks, 10.1111/j.1365-2133.2005.06563.x
  4. Leonardi Craig L., Powers Jerold L., Matheson Robert T., Goffe Bernard S., Zitnik Ralph, Wang Andrea, Gottlieb Alice B., Etanercept as Monotherapy in Patients with Psoriasis, 10.1056/nejmoa030409
  5. Gottlieb Alice B., Evans Robert, Li Shu, Dooley Lisa T., Guzzo Cynthia A., Baker Daniel, Bala Mohan, Marano Colleen W., Menter Alan, Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial, 10.1016/j.jaad.2004.02.021
  6. Gordon Kenneth B., Langley Richard G., Leonardi Craig, Toth Darryl, Menter M. Alan, Kang Sewon, Heffernan Michael, Miller Bruce, Hamlin Regina, Lim Liberata, Zhong Jianhua, Hoffman Rebecca, Okun Martin M., Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study, 10.1016/j.jaad.2006.05.027
  7. Krueger Gerald G., Langley Richard G., Leonardi Craig, Yeilding Newman, Guzzo Cynthia, Wang Yuhua, Dooley Lisa T., Lebwohl Mark, A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis, 10.1056/nejmoa062382
  8. Leonardi Craig L, Kimball Alexa B, Papp Kim A, Yeilding Newman, Guzzo Cynthia, Wang Yuhua, Li Shu, Dooley Lisa T, Gordon Kenneth B, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1), 10.1016/s0140-6736(08)60725-4
  9. Abuabara Katrina, Wan Joy, Troxel Andrea B., Shin Daniel B., Van Voorhees Abby S., Bebo Bruce F., Krueger Gerald G., Callis Duffin Kristina, Gelfand Joel M., Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis, 10.1016/j.jaad.2012.07.007
  10. Papp Kim A, Langley Richard G, Lebwohl Mark, Krueger Gerald G, Szapary Philippe, Yeilding Newman, Guzzo Cynthia, Hsu Ming-Chun, Wang Yuhua, Li Shu, Dooley Lisa T, Reich Kristian, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), 10.1016/s0140-6736(08)60726-6
  11. Griffiths Christopher E.M., Strober Bruce E., van de Kerkhof Peter, Ho Vincent, Fidelus-Gort Roseanne, Yeilding Newman, Guzzo Cynthia, Xia Yichuan, Zhou Bei, Li Shu, Dooley Lisa T., Goldstein Neil H., Menter Alan, Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis, 10.1056/nejmoa0810652
  12. Kimball A.B., Papp K.A., Wasfi Y., Chan D., Bissonnette R., Sofen H., Yeilding N., Li S., Szapary P., Gordon K.B., , Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study : Ustekinumab treatment through 5 years in psoriasis, 10.1111/jdv.12046
  13. Geng Dong, Shankar Gopi, Schantz Allen, Rajadhyaksha Manoj, Davis Hugh, Wagner Carrie, Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies, 10.1016/j.jpba.2005.04.045
  14. Lebwohl Mark, Leonardi Craig, Griffiths Christopher E.M., Prinz Jörg C., Szapary Philippe O., Yeilding Newman, Guzzo Cynthia, Li Shu, Hsu Ming-Chun, Strober Bruce, Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials, 10.1016/j.jaad.2011.06.011
  15. Miniño, Natl Vital Stat Rep, 59, 1 (2011)
  16. National Cancer Institute Surveillance, Epidemiology and End Results
  17. Trinchieri Giorgio, Pflanz Stefan, Kastelein Robert A, The IL-12 Family of Heterodimeric Cytokines, 10.1016/s1074-7613(03)00296-6
  18. Wakkee Marlies, de Vries Esther, van den Haak Pieter, Nijsten Tamar, Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort, 10.1016/j.jaad.2010.08.036
  19. FRENTZ, OLSEN, Malignant tumours and psoriasis: a follow-up study, 10.1046/j.1365-2133.1999.02655.x
  20. KRATHEN M. S., GOTTLIEB A. B., MEASE P. J., Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis, 10.3899/jrheum.100041
  21. Langowski John L., Zhang Xueqing, Wu Lingling, Mattson Jeanine D., Chen Taiying, Smith Kathy, Basham Beth, McClanahan Terrill, Kastelein Robert A., Oft Martin, IL-23 promotes tumour incidence and growth, 10.1038/nature04808
  22. Brauchli Yolanda B., Jick Susan S., Miret Montserrat, Meier Christoph R., Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Case–Control Analysis, 10.1038/jid.2009.113
  23. Gelfand Joel M., Neimann Andrea L., Shin Daniel B., Wang Xingmei, Margolis David J., Troxel Andrea B., Risk of Myocardial Infarction in Patients With Psoriasis, 10.1001/jama.296.14.1735
  24. Patel Rita V., Shelling Michael L., Prodanovich Srdjan, Federman Daniel G., Kirsner Robert S., Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature, 10.1007/s11606-011-1698-5
  25. Reich, J Drugs Dermatol, 11, 300 (2012)
  26. Gordon Kenneth B., Papp Kim A., Langley Richard G., Ho Vincent, Kimball Alexa B., Guzzo Cynthia, Yeilding Newman, Szapary Philippe O., Fakharzadeh Steven, Li Shu, Hsu Ming-Chun, Reich Kristian, Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials, 10.1016/j.jaad.2011.06.041
  27. Kimball Alexa B., Szapary Philippe, Mrowietz Ulrich, Reich Kristian, Langley Richard G., You Yin, Hsu Ming-Chun, Yeilding Newman, Rader Daniel J., Mehta Nehal N., Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis, 10.1016/j.jaad.2011.06.035
  28. Fieschi Claire, Casanova Jean-Laurent, Mini-review The role of interleukin-12 in human infectious diseases: only a faint signature, 10.1002/eji.200324038
  29. van de Vosse Esther, Ottenhoff Tom H.M., Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity, 10.1016/j.micinf.2005.10.032
  30. Filipe-Santos Orchidée, Bustamante Jacinta, Chapgier Ariane, Vogt Guillaume, de Beaucoudrey Ludovic, Feinberg Jacqueline, Jouanguy Emmanuelle, Boisson-Dupuis Stéphanie, Fieschi Claire, Picard Capucine, Casanova Jean-Laurent, Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features, 10.1016/j.smim.2006.07.010
  31. Kagami S., Rizzo H. L., Kurtz S. E., Miller L. S., Blauvelt A., IL-23 and IL-17A, but Not IL-12 and IL-22, Are Required for Optimal Skin Host Defense against Candida albicans, 10.4049/jimmunol.1001153
  32. Puel A., Cypowyj S., Bustamante J., Wright J. F., Liu L., Lim H. K., Migaud M., Israel L., Chrabieh M., Audry M., Gumbleton M., Toulon A., Bodemer C., El-Baghdadi J., Whitters M., Paradis T., Brooks J., Collins M., Wolfman N. M., Al-Muhsen S., Galicchio M., Abel L., Picard C., Casanova J.-L., Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity, 10.1126/science.1200439
  33. Menter, J Drugs Dermatol, 7, 1137 (2008)
  34. Leonardi Craig, Papp Kim, Strober Bruce, Reich Kristian, Asahina Akihiko, Gu Yihua, Beason Joseph, Rozzo Stephen, Tyring Stephen, The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis : A Comprehensive Analysis of All Adalimumab Exposure in All Clinical Trials, 10.2165/11587890-000000000-00000
  35. Burmester Gerd R, Panaccione Remo, Gordon Kenneth B, McIlraith Melissa J, Lacerda Ana P M, Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease, 10.1136/annrheumdis-2011-201244
  36. Tsai T.-F., Chiu H.-Y., Song M., Chan D., A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial : Correspondence, 10.1111/j.1365-2133.2012.11162.x
  37. Pariser David M., Leonardi Craig L., Gordon Kenneth, Gottlieb Alice B., Tyring Stephen, Papp Kim A., Li Joanne, Baumgartner Scott W., Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis, 10.1016/j.jaad.2011.07.040
  38. Papp Kim A., Poulin Yves, Bissonnette Robert, Bourcier Marc, Toth Darryl, Rosoph Leslie, Poulin-Costello Melanie, Setterfield Mike, Syrotuik Jerry, Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population, 10.1016/j.jaad.2010.07.026
  39. Yong M Schenfeld J Anthony M Kimball AB Incidence rates of malignancies and hospitalized infectious events in psoriasis patients with or without treatment and a general population in the US: 2005-2009 American Academy of Dermatology Annual Meeting
  40. Patel Rita V., Clark Lily N., Lebwohl Mark, Weinberg Jeffrey M., Treatments for psoriasis and the risk of malignancy, 10.1016/j.jaad.2008.12.031
  41. Stricklin Sherea M., Stoecker William V., Malters Joseph M., Drugge Rhett, Oliviero Margaret, Rabinovitz Harold S., Perry Lindall A., Melanoma in situ in a private practice setting 2005 through 2009: Location, lesion size, lack of concern, 10.1016/j.jaad.2011.11.949
  42. Mocellin S., Nitti D., Cutaneous Melanoma In Situ: Translational Evidence from a Large Population-Based Study, 10.1634/theoncologist.2010-0340
  43. O’Reilly Zwald Fiona, Brown Marc, Skin cancer in solid organ transplant recipients: Advances in therapy and management, 10.1016/j.jaad.2010.11.062
  44. Rubin Adam I., Chen Elbert H., Ratner Désirée, Basal-Cell Carcinoma, 10.1056/nejmra044151
  45. Engels Eric A., Pfeiffer Ruth M., Fraumeni Joseph F., Kasiske Bertram L., Israni Ajay K., Snyder Jon J., Wolfe Robert A., Goodrich Nathan P., Bayakly A. Rana, Clarke Christina A., Copeland Glenn, Finch Jack L., Fleissner Mary Lou, Goodman Marc T., Kahn Amy, Koch Lori, Lynch Charles F., Madeleine Margaret M., Pawlish Karen, Rao Chandrika, Williams Melanie A., Castenson David, Curry Michael, Parsons Ruth, Fant Gregory, Lin Monica, Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients, 10.1001/jama.2011.1592
  46. Ahlehoff Ole, Gislason Gunnar H., Jørgensen Casper H., Lindhardsen Jesper, Charlot Mette, Olesen Jonas B., Abildstrøm Steen Z., Skov Lone, Torp-Pedersen Christian, Hansen Peter Riis, Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study, 10.1093/eurheartj/ehr285
  47. Mehta Nehal N., Yu YiDing, Pinnelas Rebecca, Krishnamoorthy Parasuram, Shin Daniel B., Troxel Andrea B., Gelfand Joel M., Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events, 10.1016/j.amjmed.2011.03.028
  48. Mehta N. N., Azfar R. S., Shin D. B., Neimann A. L., Troxel A. B., Gelfand J. M., Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database, 10.1093/eurheartj/ehp567
  49. Micha Renata, Imamura Fumiaki, Wyler von Ballmoos Moritz, Solomon Daniel H., Hernán Miguel A., Ridker Paul M., Mozaffarian Dariush, Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease, 10.1016/j.amjcard.2011.06.054
  50. Westlake S. L., Colebatch A. N., Baird J., Kiely P., Quinn M., Choy E., Ostor A. J. K., Edwards C. J., The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review, 10.1093/rheumatology/kep366
  51. Westlake S. L., Colebatch A. N., Baird J., Curzen N., Kiely P., Quinn M., Choy E., Ostor A. J. K., Edwards C. J., Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review, 10.1093/rheumatology/keq316
  52. Abuabara K., Lee H., Kimball A.B., The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study : Psoriasis treatment and risk of MI, 10.1111/j.1365-2133.2011.10525.x
  53. Wu Jashin J., Poon Kwun-Yee T., Channual Jennifer C., Shen Albert Yuh-Jer, Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis, 10.1001/archdermatol.2012.2502
  54. Reich K., Langley R.G., Lebwohl M., Szapary P., Guzzo C., Yeilding N., Li S., Hsu M-C., Griffiths C.E.M., Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies : Cardiovascular safety of ustekinumab in clinical trials of psoriasis, 10.1111/j.1365-2133.2011.10257.x
  55. Ryan Caitriona, Leonardi Craig L., Krueger James G., Kimball Alexa B., Strober Bruce E., Gordon Kenneth B., Langley Richard G., de Lemos James A., Daoud Yahya, Blankenship Derek, Kazi Salahuddin, Kaplan Daniel H., Friedewald Vincent E., Menter Alan, Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events : A Meta-analysis of Randomized Controlled Trials, 10.1001/jama.2011.1211
  56. Tzellos T., Kyrgidis A., Zouboulis C. C., Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials : MACEs in patients treated with anti-IL-12/23 agents, 10.1111/j.1468-3083.2012.04500.x
  57. Papp, J Drugs Dermatol, 11, 1210 (2012)
  58. Burden A.D., Warren R.B., Kleyn C.E., McElhone K., Smith C.H., Reynolds N.J., Ormerod A.D., Griffiths C.E.M., , The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives : Development and methodology of BADBIR, 10.1111/j.1365-2133.2012.10835.x